Hengrui Pharma Subsidiary Receives Approval for Adebeli Monoclonal Antibody Clinical Trial

Stock News03-06

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the National Medical Products Administration for Adebeli Monoclonal Antibody Injection, with clinical trials scheduled to commence in the near future. In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the Adebeli Monoclonal Antibody Injection application, accepted on December 8, 2025, has been reviewed and deemed to meet the requirements for drug registration, granting approval for the initiation of clinical trials. The specific trial is a randomized, double-blind, multicenter Phase III clinical study evaluating Adebeli Monoclonal Antibody (SHR-1316) combined with Tegafur, Gimeracil, and Oteracil Potassium (S-1) and Oxaliplatin (SOX) versus a placebo combined with S-1 and Oxaliplatin for the perioperative treatment of resectable gastric or gastroesophageal junction cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172641395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172641395","market":"us","top_or_hot":-1,"title":"Hengrui Pharma Subsidiary Receives Approval for Adebeli Monoclonal Antibody Clinical Trial","media":"Stock News","content":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the National Medical Products Administration for Adebeli Monoclonal Antibody Injection, with clinical trials scheduled to commence in the near future. In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the Adebeli Monoclonal Antibody Injection application, accepted on December 8, 2025, has been reviewed and deemed to meet the requirements for drug registration, granting approval for the initiation of clinical trials. The specific trial is a randomized, double-blind, multicenter Phase III clinical study evaluating Adebeli Monoclonal Antibody (SHR-1316) combined with Tegafur, Gimeracil, and Oteracil Potassium (S-1) and Oxaliplatin (SOX) versus a placebo combined with S-1 and Oxaliplatin for the perioperative treatment of resectable gastric or gastroesophageal junction cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hengrui Pharma Subsidiary Receives Approval for Adebeli Monoclonal Antibody Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHengrui Pharma Subsidiary Receives Approval for Adebeli Monoclonal Antibody Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the National Medical Products Administration for Adebeli Monoclonal Antibody Injection, with clinical trials scheduled to commence in the near future. In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the Adebeli Monoclonal Antibody Injection application, accepted on December 8, 2025, has been reviewed and deemed to meet the requirements for drug registration, granting approval for the initiation of clinical trials. The specific trial is a randomized, double-blind, multicenter Phase III clinical study evaluating Adebeli Monoclonal Antibody (SHR-1316) combined with Tegafur, Gimeracil, and Oteracil Potassium (S-1) and Oxaliplatin (SOX) versus a placebo combined with S-1 and Oxaliplatin for the perioperative treatment of resectable gastric or gastroesophageal junction cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1997244956.HKD","symbol_name":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","start_time":0,"source_url":"","article_id":"1172641395","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172641395","pubTimestamp":1772788856,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600276":"恒瑞医药","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","01276":"恒瑞医药","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","BK0196":"行业龙头","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","BK0060":"抗癌","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0239":"医药制造","BK0028":"国家队","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","BK0183":"MSCI概念","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1191":"制药","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK0012":"证金概念","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK0188":"融资融券"},"translate_title":"恒瑞医药子公司Adebeli单抗临床试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1,"01276":1},"content_text":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the National Medical Products Administration for Adebeli Monoclonal Antibody Injection, with clinical trials scheduled to commence in the near future. In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, the Adebeli Monoclonal Antibody Injection application, accepted on December 8, 2025, has been reviewed and deemed to meet the requirements for drug registration, granting approval for the initiation of clinical trials. The specific trial is a randomized, double-blind, multicenter Phase III clinical study evaluating Adebeli Monoclonal Antibody (SHR-1316) combined with Tegafur, Gimeracil, and Oteracil Potassium (S-1) and Oxaliplatin (SOX) versus a placebo combined with S-1 and Oxaliplatin for the perioperative treatment of resectable gastric or gastroesophageal junction cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172641395","isCrawlerRequest":true}